L-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro

Experimental Neurology

Volumn 238, Issue 1, 2012, Pages 29-37

  Chan, Sandra W ^a   Dunlop, Rachael A ^a   Rowe, Anthony ^b   Double, Kay L ^c   Rodgers, Kenneth J ^a,d  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Incorporation; L DOPA; L tyrosine; Parkinson's disease; Protein

Indexed keywords

BRAIN PROTEIN; LEVODOPA; TYROSINE;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; AUTOPHAGY; BRAIN REGION; CELL FUNCTION; CELL STIMULATION; CELL VACUOLE; CLINICAL ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MITOCHONDRION; NEUROBLASTOMA CELL; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN METABOLISM; PROTEIN MODIFICATION;

ANTIPARKINSON AGENTS; APOPTOSIS; BLOOD PROTEIN ELECTROPHORESIS; BRAIN CHEMISTRY; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA FRAGMENTATION; HUMANS; HYDROLYSIS; INDICATORS AND REAGENTS; L-LACTATE DEHYDROGENASE; LEVODOPA; MICROSCOPY, ELECTRON; MICROSCOPY, FLUORESCENCE; MITOCHONDRIAL MEMBRANES; NERVE TISSUE PROTEINS; NEUROTOXINS; OXIDATION-REDUCTION; PARKINSON DISEASE; QUINOLINES;

EID: 84866547129     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.09.029     Document Type: Article

References (31)

1. Basma A.N., Morris E.J., Nicklas W.J., Geller H.M. l-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J. Neurochem. 1995, 64:825-832.
2. Blunt S.B., Jenner P., Marsden C.D. Suppressive effect of l-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov. Disord. 1993, 8:129-133.
3. Clement M.V., Long L.H., Ramalingam J., Halliwell B. The cytotoxicity of dopamine may be an artefact of cell culture. J. Neurochem. 2002, 81:414-421.
4. Dickson D.W., Braak H., Duda J.E., Duyckaerts C., Gasser T., Halliday G.M., Hardy J., Leverenz J.B., Del Tredici K., Wszolek Z.K., Litvan I. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 2009, 8:1150-1157.
5. Dunlop R.A., Dean R.T., Rodgers K.J. The impact of specific oxidized amino acids on protein turnover in J774 cells. Biochem. J. 2008, 410:131-140.
6. Emdadul Haque M., Asanuma M., Higashi Y., Miyazaki I., Tanaka K., Ogawa N. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim. Biophys. Acta 2003, 1619:39-52.
7. Ericsson C., Peredo I., Nister M. Optimized protein extraction from cryopreserved brain tissue samples. Acta Oncol. 2007, 46:10-20.
8. Fahn S. Levodopa in the treatment of Parkinson's disease. J. Neural Transm. Suppl. 2006, 71:1-15.
9. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 2004, 351:2498-2508.
10. Fu S., Dean R., Southan M., Truscott R. The hydroxyl radical in lens nuclear cataractogenesis. J. Biol. Chem. 1998, 273:28603-28609.
11. Gieseg S.P., Simpson J.A., Charlton T.S., Duncan M.W., Dean R.T. Protein-bound 3, 4-dihydroxyphenylalanine is a major reductant formed during hydroxyl radical damage to proteins. Biochemistry 1993, 32:4780-4786.
12. Kostic V., Przedborski S., Flaster E., Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991, 41:202-205.
13. Lai C.T., Yu P.H. Dopamine- and l-beta-3, 4-dihydroxyphenylalanine hydrochloride (l-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem. Pharmacol. 1997, 53:363-372.
14. Lee J.W., Beebe K., Nangle L.A., Jang J., Longo-Guess C.M., Cook S.A., Davisson M.T., Sundberg J.P., Schimmel P., Ackerman S.L. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature 2006, 443:50-55.
15. Lyras L., Zeng B.Y., McKenzie G., Pearce R.K., Halliwell B., Jenner P. Chronic high dose l-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J. Neural Transm. 2002, 109:53-67.
16. Migheli R., Godani C., Sciola L., Delogu M.R., Serra P.A., Zangani D., De Natale G., Miele E., Desole M.S. Enhancing effect of manganese on l-DOPA-induced apoptosis in PC12 cells: role of oxidative stress. J. Neurochem. 1999, 73:1155-1163.
17. Muller T., Hefter H., Hueber R., Jost W.H., Leenders K.L., Odin P., Schwarz J. Is levodopa toxic?. J. Neurol. 2004, 251(Suppl 6):VI/44-VI/46.
18. Ndubuizu O., LaManna J.C. Brain tissue oxygen concentration measurements. Antioxid. Redox Signal. 2007, 9:1207-1219.
19. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Damier P., De Yebenes J., Gershanik O., Guttman M., Grandas F., Hallett M., Hornykiewicz O., Jenner P., Katzenschlager R., Langston W.J., LeWitt P., Melamed E., Mena M.A., Michel P.P., Mytilineou C., Obeso J.A., Poewe W., Quinn N., Raisman-Vozari R., Rajput A.H., Rascol O., Sampaio C., Stocchi F. Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Disord. 2004, 19:997-1005.
20. Ozawa K., Headlam M.J., Mouradov D., Watt S.J., Beck J.L., Rodgers K.J., Dean R.T., Huber T., Otting G., Dixon N.E. Translational incorporation of l-3, 4-dihydroxyphenylalanine into proteins. FEBS J. 2005, 272:3162-3171.
21. Pardo B., Mena M.A., Casarejos M.J., Paino C.L., De Yebenes J.G. Toxic effects of l-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 1995, 682:133-143.
22. Paz M.A., Fluckiger R., Boak A., Kagan H.M., Gallop P.M. Specific detection of quinoproteins by redox-cycling staining. J. Biol. Chem. 1991, 266:689-692.
23. Rajput A.H., Fenton M.E., Birdi S., Macaulay R., George D., Rozdilsky B., Ang L.C., Senthilselvan A., Hornykiewicz O. Clinical-pathological study of levodopa complications. Mov. Disord. 2002, 17:289-296.
24. Rodgers K.J., Dean R.T. The metabolism of protein-bound DOPA in mammals. Int. J. Biochem. Cell Biol. 2000, 32:945-955.
25. Rodgers K.J., Hume P.M., Dunlop R.A., Dean R.T. Biosynthesis and turnover of DOPA-containing proteins by human cells. Free Radic. Biol. Med. 2004, 37:1756-1764.
26. Rodgers K.J., Hume P.M., Morris J.G., Dean R.T. Evidence for l-dopa incorporation into cell proteins in patients treated with levodopa. J. Neurochem. 2006, 98(4):1061-1070.
27. Rodgers K.J., Wang H., Fu S., Dean R.T. Biosynthetic incorporation of oxidized amino acids into proteins and their cellular proteolysis. Free Radic. Biol. Med. 2002, 32:766-775.
28. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
29. Sun M.G., Williams J., Munoz-Pinedo C., Perkins G.A., Brown J.M., Ellisman M.H., Green D.R., Frey T.G. Correlated three-dimensional light and electron microscopy reveals transformation of mitochondria during apoptosis. Nat. Cell Biol. 2007, 9:1057-1065.
30. Toth C., Breithaupt K., Ge S., Duan Y., Terris J.M., Thiessen A., Wiebe S., Zochodne D.W., Suchowersky O. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann. Neurol. 2010, 68:28-36.
31. Waelti E.R., Barton M. Rapid endocytosis of copper-zinc superoxide dismutase into human endothelial cells: role for its vascular activity. Pharmacology 2006, 78:198-201.